Developer docs
API playgroundTry for free, no card

Search company profiles

Flare Capital Partners

Full company profile

uuid00000uq

Namestring
Flare Capital Partners
Legal namestring
Flare Capital Partners
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Flare Capital Partners is a Boston-based venture capital firm specializing exclusively in healthcare technology, managing approximately $1 billion in assets under management across its funds. Founded in 2013 (per the firm's homepage) with operations traceable to 2011, the firm has invested over $450 million in 83 portfolio companies and achieved 22 exits including one IPO (Bright Health Group) and multiple acquisitions (Aetion, Curisium). It invests in founders from Seed through Series B with typical checks of $5M–$30M and 10%–20% target ownership, alongside a separate Flare Scholar Ventures vehicle that deploys approximately $100,000 of pre-seed capital into companies sourced from a 509-person Flare Scholars talent network.

The firm operates a three-pillar model spanning sourcing, funding, and go-to-market acceleration. The Core Investments pillar holds Seed-to-Series B positions in companies such as Qualified Health, Suki, SmarterDx, Cohere Health, Oshi Health, knownwell, Keebler Health, Daffodil Health, and Atlas Oncology Partners. Flare Scholar Ventures is a proprietary pre-seed deal engine, and the Flare Scholars Program is an annual professional development community of 509 emerging leaders. Wrapping these pillars are two proprietary network products: a 35-member Industry Advisory Board whose member companies represent approximately $1.2 trillion in revenue, ~15% of U.S. healthcare spend, 68.5 million insured lives, and 35,210 hospital beds; and a 14-member AI Advisory Council including senior leaders from Microsoft, AWS, Amgen, CVS Health, GuideWell, Banner Health, and MedStar Health. The Strategic Engagement Model operationalizes these networks, contributing approximately $1 billion in direct revenue to portfolio companies through buyer introductions.

The business model is classic venture capital: recurring management fees on committed capital under a fund-of-funds structure, supplemented by realized carried interest on exits. Distribution is purely domestic U.S. and is relationship-driven rather than transactional, leveraging IAB referrals, AI Council pilots, and Flare Scholars deal flow rather than any public product. The firm is privately held with no disclosed parent company; Michael Greeley serves as Co-Founder and General Partner, Adam Bruce as Partner, CFO and COO, and a team of approximately 24 investment professionals and executive partners (including former CDC Director Dr. Rochelle Walensky and former Partners HealthCare CEO Gary Gottlieb MD).

Short descriptiontext

Flare Capital Partners is a Boston-based healthtech venture capital firm managing ~$1B AUM across 83 portfolio companies and 22 exits. It invests Seed-to-Series B alongside a pre-seed Scholar Ventures vehicle, supported by a 35-member Industry Advisory Board and 14-member AI Advisory Council driving ~$1B in portfolio revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
healthtech venture capital, early-stage healthcare investing, seed to series B investing, pre-seed deal sourcing, portfolio acceleration platform
Industry3 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)
NAICS code2 codes
  • Investment Banking and Securities Intermediation523150
  • Portfolio Management and Investment Advice523940
SIC code2 codes
  • Security Brokers, Dealers & Flotation Companies6211
  • Investment Advice6282
Product category
Healthcare Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management (implied)
TypeManaged Services
Description

Manages approximately $1B in assets under management across the firm's healthtech-focused venture funds, generating recurring management fees on committed capital.

flarecapital.com
2Portfolio Exits / Carried Interest (implied)
TypeLicensing Royalties
Description

Realizes returns through 22 portfolio company exits to date (with Aetion and Curisium among acquired companies; Bright Health Group among IPO'd companies; Iora Health, Docent, Valence Health among exited). Returns are recycled through 10%-20% target ownership stakes in 83 portfolio companies.

flarecapital.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details2 tiers
1Core Investments: Seed to Series B, $5M-$30M total investment per company, 10%-20% target ownership
ModelOtherBilling cadenceMulti-year contract
Notes

Investment stage range from Seed through Series B. Typical check size $5M to $30M. Target ownership 10%-20%.

flarecapital.com
2Flare Scholar Ventures: ~$100K pre-seed ticket to companies founded, advised, or supported by Flare Scholars network
ModelOtherBilling cadencePay-as-you-go
Notes

Proprietary deal-discovery engine deploying pre-seed capital to companies in the Flare Scholars talent network.

flarecapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Flare Scholar Ventures
Description

Proprietary pre-seed deal engine deploying ~$100K of capital to back companies founded, advised, or supported by the Flare Scholars network.

flarecapital.com
+1 more record
Core offering1 text field

Flare Capital Partners provides venture capital investment, network-driven portfolio acceleration, and talent-community engagement exclusively to U.S. healthcare technology founders. Its primary offering is direct equity investment of $5 million to $30 million per company across Seed to Series B rounds with 10%–20% target ownership, complemented by a ~$100K pre-seed vehicle (Flare Scholar Ventures), a 35-member Industry Advisory Board opening enterprise buyer relationships, a 14-member AI Advisory Council supporting AI deployments, and a 509-member Flare Scholars talent community that sources both deals and operating talent.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • ~$1B in assets under management
+11 more records
Product overview1 text field

Flare Capital Partners is a healthtech-focused venture capital firm, not a SaaS product company; its offering is a multi-vehicle investment platform built around three coordinated pillars. The Core Investments pillar partners with founders from Seed through Series B (typical checks $5M–$30M, target ownership 10%–20%), and houses the majority of named portfolio products such as Qualified Health, Suki, SmarterDx, Cohere Health, Oshi Health, knownwell, Peer AI, Cascala Health, Isaac Health, Keebler Health, Atlas Oncology Partners, Daffodil Health, Photon Health, Layer Health, and Lynx. Flare Scholar Ventures is a proprietary pre-seed deal engine deploying approximately $100K into companies sourced from the Flare Scholars Program, a 509-person annual talent and mentorship community. Wrapping these pillars are two network products that operationalize the firm’s strategic engagement: a 35-member Industry Advisory Board representing ~15% of U.S. healthcare spend, and a 14-member AI Advisory Council that supports portfolio AI deployments. Together, these pillars form a single connected healthtech investment platform spanning sourcing (Scholars), funding (Scholar Ventures + Core), and go-to-market acceleration (IAB + AI Council).

Product and service5 records
1Core Investments (Seed-to-Series B venture capital)
CategoryHealthcare Venture Capital Investment
Description

The firm's primary investment offering: direct equity capital of $5M–$30M per company in U.S. healthtech founders at Seed through Series B, targeting 10%–20% ownership, with multi-cycle support and access to the Strategic Engagement Model, Industry Advisory Board, and AI Advisory Council. For healthtech founders seeking institutional venture capital.

2Flare Scholar Ventures (pre-seed investment vehicle)
CategoryPre-Seed Healthcare Venture Capital
Description

A proprietary pre-seed investment engine that deploys approximately $100K of equity capital into companies founded, advised, or supported by members of the 509-strong Flare Scholars talent network. For very early-stage healthtech founders affiliated with the Flare Scholars community.

3Industry Advisory Board engagement (buyer introductions)
CategoryPortfolio Acceleration Service
Description

A 35-member advisory board of senior healthcare executives from organizations representing ~$1.2T in revenue and ~15% of all U.S. healthcare spend, providing portfolio founders with frontline market intelligence, buyer introductions, and partnership pathways. Bundled with Core Investments for portfolio companies.

4AI Advisory Council engagement
CategoryPortfolio Acceleration Service
Description

A 14-member advisory council of senior AI and healthcare leaders from organizations including Microsoft, AWS, Amgen, CVS Health, GuideWell, Banner Health, and Children's Hospital, providing structured AI evaluation, market benchmarking, and pilot pathways for AI-focused portfolio companies. Bundled with Core Investments.

5Strategic Engagement Model
CategoryPortfolio Acceleration Service
Description

The firm's proprietary matchmaking platform connecting portfolio founders with senior buyers across payers, providers, and life sciences, contributing nearly $1B in direct revenue to Flare Capital's portfolio companies. Provided to portfolio companies as part of Core Investments.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership19 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

AI Advisory Council partnership: Jared Saul (Former Chief Medical Officer, Commercial Health & Life Sciences at AWS, External Advisor) sits on the Flare Capital AI Advisory Council, supporting cloud and AI infrastructure scaling for portfolio companies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

AI Advisory Council partnership: Sean Bruich (Chief Technology Officer at Amgen) sits on the Flare Capital AI Advisory Council, providing life sciences AI deployment perspective.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

AI Advisory Council partnership: Kelly Ko (VP of Technology Ventures and Innovation at Banner Health) sits on the Flare Capital AI Advisory Council, with additional representation on the IAB. Banner Health also hosts Flare Scholars.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

AI Advisory Council partnership: Svetlana Bender, PhD (VP, AI and Behavioral Science at GuideWell & Florida Blue) sits on the Flare Capital AI Advisory Council, providing payer-side AI deployment perspective.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Industry Advisory Board partnership: Sreekanth Chaguturu, MD (EVP and Chief Medical Officer at CVS Health) represents CVS Health on Flare Capital's IAB. CVS Health is also a strategic investor via CVS Health Ventures, co-investing with Flare Capital in portfolio companies such as Oshi Health (Series C, Oct 2024) and Knownwell ($25M round, Oct 2025). Tilak Mandadi (EVP, Ventures, Chief Experience and Technology) also sits on the AI Advisory Council. CVS Health represents significant insured lives and revenue, contributing to the IAB's ~$1.2T revenue footprint.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

AI Advisory Council partnership: Peter Durlach (Former CVP, Chief Strategy Officer, Microsoft Health & Life Sciences) sits on the Flare Capital AI Advisory Council, providing Microsoft Azure / healthcare AI deployment perspective.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Industry Advisory Board partnership: Thomas Brouillard (CFO Global Care Delivery at Fresenius) sits on the Flare Capital IAB, supporting care delivery and dialysis-focused portfolio opportunities.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Industry Advisory Board partnership: Aaron Foster (VP, Business Analytics and Insights at Pfizer) sits on the Flare Capital IAB. Pfizer contributes to the IAB's $1.2T aggregate revenue footprint and supports portfolio companies with life sciences commercial pathways.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Industry Advisory Board partnership: Chase Tacker (SVP, Corporate Development at Humana) sits on the Flare Capital IAB. Humana is also a key payer partner for Greater Good Health's value-based primary care clinics.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Industry Advisory Board partnership: Susan K. Nelson (EVP and CFO at MedStar Health) sits on the Flare Capital IAB. MedStar Health ($7.7B) is also a strategic partner of Flare Capital portfolio company Suki. William Sheahan (Chief Innovation Officer & SVP) represents MedStar on the AI Advisory Council.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Industry Advisory Board partnership: Sandra L. Fenwick (CEO, Emeritus of Boston Children's Hospital) sits on the Flare Capital IAB, supporting pediatric and digital health portfolio companies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Industry Advisory Board partnership: Todd Schwarzinger sits on the Flare Capital IAB representing Cleveland Clinic, contributing clinical and operational validation pathways for portfolio companies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Industry Advisory Board partnership: Rasu B. Shrestha, MD, MBA (Enterprise EVP and Chief Innovation and Commercialization Officer at Advocate Health) sits on the Flare Capital IAB, supporting health system adoption of portfolio innovation.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Industry Advisory Board partnership: Beau Garverick (SVP, Corporate Development and Strategy at Centene) sits on the Flare Capital IAB, providing managed care and Medicaid pathway validation for portfolio companies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Industry Advisory Board partnership: Barry Stein, MD (VP, Chief Clinical Innovation Officer and Chief Medical Informatics Officer at Hartford Healthcare) sits on the Flare Capital IAB, supporting clinical innovation adoption.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Industry Advisory Board partnership: Brenton Burns (EVP at UPMC Enterprises) sits on the Flare Capital IAB, unlocking payer-provider commercialization channels for portfolio companies.

17Allina Health
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Industry Advisory Board partnership: Lawrence Cho (Chief Strategy and Growth Officer at Allina Health) sits on the Flare Capital IAB.

flarecapital.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Industry Advisory Board partnership: Brian Caveney, MD, JD, MPH (Chief Medical and Scientific Officer at Labcorp) sits on the Flare Capital IAB.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

Industry Advisory Board partnership: Jeffrey E. Graff, CFA (SVP/Treasury and Chief Corporate Development Officer at AdventHealth) sits on the Flare Capital IAB.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Multi-stage venture firm with a dedicated Health Assurance platform and deep healthtech investing practice. Directly comparable as a healthtech-focused institutional investor with operator network and similar founder partnership model.

TypeDirect peer
Description

Operates a dedicated bio/health fund ($1.5B+) investing in healthcare and life sciences companies from seed to growth. Direct peer in scale, stage range, and healthtech specialization with strong network-driven platform services.

TypeDirect peer
Description

Alphabet's venture arm with substantial healthcare practice across consumer health, digital health, and biotech. Direct peer given multi-stage healthtech investing and similar thesis on rebuilding healthcare with software, data, and AI.

TypeDirect peer
Description

Pure-play healthtech and financial services venture firm investing from seed to growth. Co-invests with Flare Capital in portfolio companies like Oshi Health, making it a direct competitor for the same healthtech AI and care delivery deals.

TypeDirect peer
Description

Pure-play healthtech venture firm led by Lynne O'Keefe and Derek Streat. Co-invests with Flare Capital in deals like Layer Health, making it a direct peer in early-to-growth stage healthtech AI and digital health investing.

TypeBroad incumbent
Description

Large multi-stage venture firm with significant healthtech and biotech practice across its portfolio. Broader incumbent that competes for healthtech deals but operates across many sectors beyond healthcare.

TypeBroad incumbent
Description

Established multi-stage venture firm with dedicated healthcare practice. Co-investor with Flare Capital in portfolio companies like Oshi Health, representing a broader incumbent competing across multiple sectors.

TypeBroad incumbent
Description

One of the largest venture firms with deep healthcare practice and significant AUM. Led Qualified Health's $125M Series B alongside Flare Capital, representing a broader incumbent with diversified stage and sector exposure.

TypeDirect peer
Description

Early-stage venture firm with strong healthcare and technology practice dating back decades. Direct peer in early-stage healthtech investing with similar focus on healthcare transformation and founder partnership.

TypeDirect peer
Description

Premier early-stage venture firm focused on life sciences, biotech, and physical sciences including healthtech. Direct peer in deep-tech healthcare investing with similar focus on transformational healthcare companies.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment120 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flare Capital Partners

Healthcare Venture Capitalflarecapital.com

Flare Capital Partners is a Boston-based healthtech venture capital firm managing ~$1B AUM across 83 portfolio companies and 22 exits. It invests Seed-to-Series B alongside a pre-seed Scholar Ventures vehicle, supported by a 35-member Industry Advisory Board and 14-member AI Advisory Council driving ~$1B in portfolio revenue.

What Flare Capital Partners does

Flare Capital Partners is a Boston-based venture capital firm specializing exclusively in healthcare technology, managing approximately $1 billion in assets under management across its funds. Founded in 2013 (per the firm's homepage) with operations traceable to 2011, the firm has invested over $450 million in 83 portfolio companies and achieved 22 exits including one IPO (Bright Health Group) and multiple acquisitions (Aetion, Curisium). It invests in founders from Seed through Series B with typical checks of $5M–$30M and 10%–20% target ownership, alongside a separate Flare Scholar Ventures vehicle that deploys approximately $100,000 of pre-seed capital into companies sourced from a 509-person Flare Scholars talent network.

The firm operates a three-pillar model spanning sourcing, funding, and go-to-market acceleration. The Core Investments pillar holds Seed-to-Series B positions in companies such as Qualified Health, Suki, SmarterDx, Cohere Health, Oshi Health, knownwell, Keebler Health, Daffodil Health, and Atlas Oncology Partners. Flare Scholar Ventures is a proprietary pre-seed deal engine, and the Flare Scholars Program is an annual professional development community of 509 emerging leaders. Wrapping these pillars are two proprietary network products: a 35-member Industry Advisory Board whose member companies represent approximately $1.2 trillion in revenue, ~15% of U.S. healthcare spend, 68.5 million insured lives, and 35,210 hospital beds; and a 14-member AI Advisory Council including senior leaders from Microsoft, AWS, Amgen, CVS Health, GuideWell, Banner Health, and MedStar Health. The Strategic Engagement Model operationalizes these networks, contributing approximately $1 billion in direct revenue to portfolio companies through buyer introductions.

The business model is classic venture capital: recurring management fees on committed capital under a fund-of-funds structure, supplemented by realized carried interest on exits. Distribution is purely domestic U.S. and is relationship-driven rather than transactional, leveraging IAB referrals, AI Council pilots, and Flare Scholars deal flow rather than any public product. The firm is privately held with no disclosed parent company; Michael Greeley serves as Co-Founder and General Partner, Adam Bruce as Partner, CFO and COO, and a team of approximately 24 investment professionals and executive partners (including former CDC Director Dr. Rochelle Walensky and former Partners HealthCare CEO Gary Gottlieb MD).

Flare Capital Partners firmographics

Firmographics
Name
Flare Capital Partners
Legal name
Flare Capital Partners
Website
https://flarecapital.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
Flare Capital Partners is a Boston-based healthtech venture capital firm managing ~$1B AUM across 83 portfolio companies and 22 exits. It invests Seed-to-Series B alongside a pre-seed Scholar Ventures vehicle, supported by a 35-member Industry Advisory Board and 14-member AI Advisory Council driving ~$1B in portfolio revenue.
Ownership category
akta.pro rank

Flare Capital Partners industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Investment Banking and Securities Intermediation (523150), Portfolio Management and Investment Advice (523940)
SIC
Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAM
Accelerators & Incubators (Investor-Operated)

Keywords

  • Healthtech venture capital
  • Early-stage healthcare investing
  • Seed to series B investing
  • Pre-seed deal sourcing
  • Portfolio acceleration platform

Where Flare Capital Partners is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Flare Capital Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Fund Management (implied): Manages approximately $1B in assets under management across the firm's healthtech-focused venture funds, generating recurring management fees on committed capital.
  2. Portfolio Exits / Carried Interest (implied): Realizes returns through 22 portfolio company exits to date (with Aetion and Curisium among acquired companies; Bright Health Group among IPO'd companies; Iora Health, Docent, Valence Health among exited). Returns are recycled through 10%-20% target ownership stakes in 83 portfolio companies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCore Investments: Seed to Series B, $5M-$30M total investment per company, 10%-20% target ownership
OtherPay-as-you-goFlare Scholar Ventures: ~$100K pre-seed ticket to companies founded, advised, or supported by Flare Scholars network

Go-to-market motion1 record

Distribution channels4 records

Marketing channels11 records

Flare Capital Partners product offering

Product offering

Core offering

Flare Capital Partners provides venture capital investment, network-driven portfolio acceleration, and talent-community engagement exclusively to U.S. healthcare technology founders. Its primary offering is direct equity investment of $5 million to $30 million per company across Seed to Series B rounds with 10%–20% target ownership, complemented by a ~$100K pre-seed vehicle (Flare Scholar Ventures), a 35-member Industry Advisory Board opening enterprise buyer relationships, a 14-member AI Advisory Council supporting AI deployments, and a 509-member Flare Scholars talent community that sources both deals and operating talent.

Product overview

Flare Capital Partners is a healthtech-focused venture capital firm, not a SaaS product company; its offering is a multi-vehicle investment platform built around three coordinated pillars. The Core Investments pillar partners with founders from Seed through Series B (typical checks $5M–$30M, target ownership 10%–20%), and houses the majority of named portfolio products such as Qualified Health, Suki, SmarterDx, Cohere Health, Oshi Health, knownwell, Peer AI, Cascala Health, Isaac Health, Keebler Health, Atlas Oncology Partners, Daffodil Health, Photon Health, Layer Health, and Lynx. Flare Scholar Ventures is a proprietary pre-seed deal engine deploying approximately $100K into companies sourced from the Flare Scholars Program, a 509-person annual talent and mentorship community. Wrapping these pillars are two network products that operationalize the firm’s strategic engagement: a 35-member Industry Advisory Board representing ~15% of U.S. healthcare spend, and a 14-member AI Advisory Council that supports portfolio AI deployments. Together, these pillars form a single connected healthtech investment platform spanning sourcing (Scholars), funding (Scholar Ventures + Core), and go-to-market acceleration (IAB + AI Council).

Differentiator

Problem solved

Functional benefit

Brands

  • Flare Scholar Ventures: Proprietary pre-seed deal engine deploying ~$100K of capital to back companies founded, advised, or supported by the Flare Scholars network.
  • Flare Scholars

Products and services

  • Core Investments (Seed-to-Series B venture capital) The firm's primary investment offering: direct equity capital of $5M–$30M per company in U.S. healthtech founders at Seed through Series B, targeting 10%–20% ownership, with multi-cycle support and access to the Strategic Engagement Model, Industry Advisory Board, and AI Advisory Council. For healthtech founders seeking institutional venture capital.
  • Flare Scholar Ventures (pre-seed investment vehicle) A proprietary pre-seed investment engine that deploys approximately $100K of equity capital into companies founded, advised, or supported by members of the 509-strong Flare Scholars talent network. For very early-stage healthtech founders affiliated with the Flare Scholars community.
  • Industry Advisory Board engagement (buyer introductions) A 35-member advisory board of senior healthcare executives from organizations representing ~$1.2T in revenue and ~15% of all U.S. healthcare spend, providing portfolio founders with frontline market intelligence, buyer introductions, and partnership pathways. Bundled with Core Investments for portfolio companies.
  • AI Advisory Council engagement A 14-member advisory council of senior AI and healthcare leaders from organizations including Microsoft, AWS, Amgen, CVS Health, GuideWell, Banner Health, and Children's Hospital, providing structured AI evaluation, market benchmarking, and pilot pathways for AI-focused portfolio companies. Bundled with Core Investments.
  • Strategic Engagement Model The firm's proprietary matchmaking platform connecting portfolio founders with senior buyers across payers, providers, and life sciences, contributing nearly $1B in direct revenue to Flare Capital's portfolio companies. Provided to portfolio companies as part of Core Investments.

Quantifiable outcome

  • ~$1B in assets under management
  • +11 more outcomes

Companies that use Flare Capital Partners

Customer profile

Named customers15 records

Segments4 records

Ideal customer profiles3 records

Flare Capital Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Flare Capital Partners partnerships and signals

Strategic signal

Partnerships

19 partnerships are on record, tiered flagship.

  • Amazon Web Services (AWS)flagshipStrategic or Co-development Partner · 1 September 2025AI Advisory Council partnership: Jared Saul (Former Chief Medical Officer, Commercial Health & Life Sciences at AWS, External Advisor) sits on the Flare Capital AI Advisory Council, supporting cloud and AI infrastructure scaling for portfolio companies.
  • AmgenflagshipStrategic or Co-development Partner · 1 September 2025AI Advisory Council partnership: Sean Bruich (Chief Technology Officer at Amgen) sits on the Flare Capital AI Advisory Council, providing life sciences AI deployment perspective.
  • Banner HealthflagshipStrategic or Co-development Partner · 1 September 2025AI Advisory Council partnership: Kelly Ko (VP of Technology Ventures and Innovation at Banner Health) sits on the Flare Capital AI Advisory Council, with additional representation on the IAB. Banner Health also hosts Flare Scholars.
  • GuideWell / Florida BlueflagshipStrategic or Co-development Partner · 1 September 2025AI Advisory Council partnership: Svetlana Bender, PhD (VP, AI and Behavioral Science at GuideWell & Florida Blue) sits on the Flare Capital AI Advisory Council, providing payer-side AI deployment perspective.
  • CVS HealthflagshipStrategic or Co-development Partner · 1 October 2024Industry Advisory Board partnership: Sreekanth Chaguturu, MD (EVP and Chief Medical Officer at CVS Health) represents CVS Health on Flare Capital's IAB. CVS Health is also a strategic investor via CVS Health Ventures, co-investing with Flare Capital in portfolio companies such as Oshi Health (Series C, Oct 2024) and Knownwell ($25M round, Oct 2025). Tilak Mandadi (EVP, Ventures, Chief Experience and Technology) also sits on the AI Advisory Council. CVS Health represents significant insured lives and revenue, contributing to the IAB's ~$1.2T revenue footprint.
  • MicrosoftflagshipStrategic or Co-development Partner · 1 October 2024AI Advisory Council partnership: Peter Durlach (Former CVP, Chief Strategy Officer, Microsoft Health & Life Sciences) sits on the Flare Capital AI Advisory Council, providing Microsoft Azure / healthcare AI deployment perspective.
  • FreseniusflagshipStrategic or Co-development Partner · 1 March 2024Industry Advisory Board partnership: Thomas Brouillard (CFO Global Care Delivery at Fresenius) sits on the Flare Capital IAB, supporting care delivery and dialysis-focused portfolio opportunities.
  • PfizerflagshipStrategic or Co-development Partner · 1 January 2024Industry Advisory Board partnership: Aaron Foster (VP, Business Analytics and Insights at Pfizer) sits on the Flare Capital IAB. Pfizer contributes to the IAB's $1.2T aggregate revenue footprint and supports portfolio companies with life sciences commercial pathways.
  • HumanaflagshipStrategic or Co-development Partner · 1 January 2024Industry Advisory Board partnership: Chase Tacker (SVP, Corporate Development at Humana) sits on the Flare Capital IAB. Humana is also a key payer partner for Greater Good Health's value-based primary care clinics.
  • MedStar HealthflagshipStrategic or Co-development Partner · 1 January 2024Industry Advisory Board partnership: Susan K. Nelson (EVP and CFO at MedStar Health) sits on the Flare Capital IAB. MedStar Health ($7.7B) is also a strategic partner of Flare Capital portfolio company Suki. William Sheahan (Chief Innovation Officer & SVP) represents MedStar on the AI Advisory Council.
  • Boston Children's HospitalflagshipStrategic or Co-development Partner · 1 January 2024Industry Advisory Board partnership: Sandra L. Fenwick (CEO, Emeritus of Boston Children's Hospital) sits on the Flare Capital IAB, supporting pediatric and digital health portfolio companies.
  • Cleveland ClinicflagshipStrategic or Co-development Partner · 1 January 2024Industry Advisory Board partnership: Todd Schwarzinger sits on the Flare Capital IAB representing Cleveland Clinic, contributing clinical and operational validation pathways for portfolio companies.
  • Advocate HealthflagshipStrategic or Co-development Partner · 1 January 2024Industry Advisory Board partnership: Rasu B. Shrestha, MD, MBA (Enterprise EVP and Chief Innovation and Commercialization Officer at Advocate Health) sits on the Flare Capital IAB, supporting health system adoption of portfolio innovation.
  • Centene CorporationflagshipStrategic or Co-development Partner · 1 January 2024Industry Advisory Board partnership: Beau Garverick (SVP, Corporate Development and Strategy at Centene) sits on the Flare Capital IAB, providing managed care and Medicaid pathway validation for portfolio companies.
  • Hartford HealthcareflagshipStrategic or Co-development Partner · 1 October 2023Industry Advisory Board partnership: Barry Stein, MD (VP, Chief Clinical Innovation Officer and Chief Medical Informatics Officer at Hartford Healthcare) sits on the Flare Capital IAB, supporting clinical innovation adoption.
  • UPMC EnterprisesflagshipStrategic or Co-development Partner · 1 October 2023Industry Advisory Board partnership: Brenton Burns (EVP at UPMC Enterprises) sits on the Flare Capital IAB, unlocking payer-provider commercialization channels for portfolio companies.
  • Allina HealthflagshipStrategic or Co-development Partner · 1 October 2023Industry Advisory Board partnership: Lawrence Cho (Chief Strategy and Growth Officer at Allina Health) sits on the Flare Capital IAB.
  • LabcorpflagshipStrategic or Co-development Partner · 1 October 2023Industry Advisory Board partnership: Brian Caveney, MD, JD, MPH (Chief Medical and Scientific Officer at Labcorp) sits on the Flare Capital IAB.
  • AdventHealthflagshipStrategic or Co-development Partner · 1 October 2023Industry Advisory Board partnership: Jeffrey E. Graff, CFA (SVP/Treasury and Chief Corporate Development Officer at AdventHealth) sits on the Flare Capital IAB.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Flare Capital Partners competitors and assessment

Company assessment

Direct peers

  • General Catalyst: Multi-stage venture firm with a dedicated Health Assurance platform and deep healthtech investing practice. Directly comparable as a healthtech-focused institutional investor with operator network and similar founder partnership model.
  • Andreessen Horowitz (a16z Bio): Operates a dedicated bio/health fund ($1.5B+) investing in healthcare and life sciences companies from seed to growth. Direct peer in scale, stage range, and healthtech specialization with strong network-driven platform services.
  • GV (Google Ventures): Alphabet's venture arm with substantial healthcare practice across consumer health, digital health, and biotech. Direct peer given multi-stage healthtech investing and similar thesis on rebuilding healthcare with software, data, and AI.
  • Oak HC/FT: Pure-play healthtech and financial services venture firm investing from seed to growth. Co-invests with Flare Capital in portfolio companies like Oshi Health, making it a direct competitor for the same healthtech AI and care delivery deals.
  • Define Ventures: Pure-play healthtech venture firm led by Lynne O'Keefe and Derek Streat. Co-invests with Flare Capital in deals like Layer Health, making it a direct peer in early-to-growth stage healthtech AI and digital health investing.
  • Venrock: Early-stage venture firm with strong healthcare and technology practice dating back decades. Direct peer in early-stage healthtech investing with similar focus on healthcare transformation and founder partnership.
  • ARCH Venture Partners: Premier early-stage venture firm focused on life sciences, biotech, and physical sciences including healthtech. Direct peer in deep-tech healthcare investing with similar focus on transformational healthcare companies.

Broad incumbents

  • Khosla Ventures: Large multi-stage venture firm with significant healthtech and biotech practice across its portfolio. Broader incumbent that competes for healthtech deals but operates across many sectors beyond healthcare.
  • Bessemer Venture Partners: Established multi-stage venture firm with dedicated healthcare practice. Co-investor with Flare Capital in portfolio companies like Oshi Health, representing a broader incumbent competing across multiple sectors.
  • New Enterprise Associates (NEA): One of the largest venture firms with deep healthcare practice and significant AUM. Led Qualified Health's $125M Series B alongside Flare Capital, representing a broader incumbent with diversified stage and sector exposure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Flare Capital Partners social profiles

Digital presence

Flare Capital Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flare Capital Partners leadership team

Management profile

Number of profiles

Profiles18 records

Flare Capital Partners subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Flare Capital Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flare Capital Partners M&A and investment

M&A and investment

M&A

Investments120 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flare Capital Partners

What does Flare Capital Partners do?

Flare Capital Partners provides venture capital investment, network-driven portfolio acceleration, and talent-community engagement exclusively to U.S. healthcare technology founders. Its primary offering is direct equity investment of $5 million to $30 million per company across Seed to Series B rounds with 10%–20% target ownership, complemented by a ~$100K pre-seed vehicle (Flare Scholar Ventures), a 35-member Industry Advisory Board opening enterprise buyer relationships, a 14-member AI Advisory Council supporting AI deployments, and a 509-member Flare Scholars talent community that sources both deals and operating talent.

Is Flare Capital Partners a public or private company?

Flare Capital Partners is a private company. It is classified as management employee owned and is currently operating.

When was Flare Capital Partners founded?

Flare Capital Partners was founded in 2011. It employs 51 to 100 people.

Where is Flare Capital Partners based?

Flare Capital Partners is headquartered in Boston, United States, in the North America region.

How does Flare Capital Partners make money?

Two revenue lines are on record. Fund Management (implied) is the primary driver. The others are portfolio Exits / Carried Interest (implied).

Who are Flare Capital Partners's main competitors?

Direct peers on record are General Catalyst, Andreessen Horowitz (a16z Bio), GV (Google Ventures), Oak HC/FT, Define Ventures, Venrock and ARCH Venture Partners. Broad incumbents are Khosla Ventures, Bessemer Venture Partners and New Enterprise Associates (NEA).

Does Flare Capital Partners have an API?

No public API is recorded for Flare Capital Partners.

What industry is Flare Capital Partners in?

Flare Capital Partners's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523150 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Crypto BriefingAlterra Labs raises $12.5 million seed round to train medical AI in simulated clinicsAlterra Labs, a New York startup, closed a $12.5 million seed round led by Oak HC/FT to build simulated clinical environments for testing AI models. The capital will expand its evaluation and training platform, with participation from Flare Capital Partners and Company Ventures.BitlyAlterra Labs raises $12.5M seed round.Alterra Labs raised a $12.5M seed round led by Oak HC/FT, with participation from Flare Capital, Company Ventures, Tau Ventures, and angels. The funding will accelerate research, grow its in-house team of clinicians, scientists, and researchers, and build partnerships with frontier AI organizations.MorningstarKairon Health Raises $5 Million to Power AI-Driven Execution in Value-Based CareKairon Health raised $5 million in venture funding led by Flare Capital Partners to fund AI development and expansion. The company's platform serves ACOs and health systems, covering over 1 million attributed lives across 30+ states. The capital aims to support Medicare's upcoming LEAD model and increased provider risk.VenturecapitalKairon Health Secures $5M in Funding Led by Flare Capital Partners as Value-Based Care Faces Major Medicare ChangesKairon Health, a value-based care platform, secured $5 million in funding led by Flare Capital Partners. The investment will support AI development, care operations, and go-to-market growth. The funding comes as value-based care faces major Medicare changes.Tech Funding NewsEx-Bain operators raise $17M to tackle behavioural healthcare’s data blind spot with AI — TFNOnos Health, founded in 2024 by Akshay Agrawal, Josh Levitan and Suhaas Prasad, raised $17 million in Series A funding led by Costanoa, with CVS Health Ventures and Flare Capital Partners joining. The company has raised roughly $23.3 million in under a year and reports over 6% cost reductions, 35% better clinical adherence and 75% faster reviews.FinSMEsOnos Health Raises $17M in Series A FundingOnos Health raised $17M in Series A funding led by Costanoa Ventures, with participation from Flare Capital Partners and strategic investment from CVS Health Ventures. The company will use the funds to expand its AI platform and scale commercial deployments with national and regional health plans.BhbusinessOnos Health Lands $17M from Costanoa, Flare Capital, CVS VenturesOnos Health raised $17 million in a Series A round led by Costanoa Ventures, with Flare Capital and CVS Health Ventures participating. The San Francisco-based company will use the funds to accelerate selling its behavioral health quality and AI system to health plans. The platform integrates claims, utilization, and clinical documentation to identify care quality patterns.Pulse 2.0Upside Raises $20 Million Series A To Scale Housing Stability Platform For HealthcareUpside, a housing stability platform for healthcare, raised $20 million in Series A funding co-led by Aquiline and Flare Capital Partners with participation from 645 Ventures, Freestyle Capital, Triple Impact Capital, and Techstars. The company plans to use the funding for national expansion across Medicaid, Medicare Advantage, and employer-sponsored markets while deepening AI-supported delivery capabilities; Upside currently operates across 10 states and has partnerships with more than 17 national, state, and regional health plans. The company addresses housing instability as a healthcare cost driver, claiming its model delivers over 90% enrollment, stabilizes more than half of members within 90 days, and can generate up to 4x ROI in 12 months.The SaaS NewsUpside Raises $20M Series AUpside, a housing stability platform for the healthcare industry based in Fort Lauderdale, Florida, has raised $20 million in Series A funding co-led by Aquiline and Flare Capital Partners. The company plans to use the capital to expand across Medicaid, Medicare Advantage, and employer benefits markets, advance its AI-supported housing orchestration technology, and recruit new leadership. Founded in 2020 by Jake Rothstein and Peter Badgley, Upside pairs human Care Guides with AI-driven workflows to help reduce avoidable medical costs for health plan members experiencing housing instability.HIT ConsultantUpside Secures $20M to Scale AI-Driven Housing Stability Platform for HealthcareHealthcare housing stability company Upside has secured a $20M Series A funding round led by Aquiline Capital Partners, with participation from Flare Capital Partners and existing backers including 645 Ventures and Freestyle Capital, to scale its AI-driven platform. The platform addresses housing instability as a social driver of health costs, targeting $9.3 billion in annual national healthcare inpatient costs, and has demonstrated up to 4x ROI within 12 months. The company has expanded to support over 17 regional and national health plans across 10 states and plans to use the capital to grow its Medicaid and Medicare footprint while building out its employer market presence.